MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$578,503
EPS
-$0.36
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-09-30
Income taxes
0
0
-
-
Net revenues
0
0
-
-
Gross profit
0
0
-
-
Marketing expenses
52
8
176
114
General and administrative
306,796
412,023
487,041
564,683
Research and development
29,681
7,482
8,842
206,161
Stock based compensation
50,000
50,000
50,000
37,500
Total operating expenses
386,529
469,513
546,059
808,458
Loss from operations
-386,529
-469,513
-546,059
-808,458
Other income
0
5,797
-
-
Modification of warrants
0
17,505
-
24,770
Inducement of preferred shares
0
845,901
-
-
Interest expense
2,024
873
448
850
Interest expense - debt discount
70,211
42,175
27,704
263,719
Interest expense - original issuance costs
119,739
81,017
94,353
99,126
Total other expense
-191,974
-981,674
-122,505
-388,465
Loss before income taxes
-578,503
-1,451,187
-668,564
-1,196,923
Net loss
-578,503
-1,451,187
-668,564
-1,196,923
Basic EPS
-0.36
-0.9
-0.42
-0.94
Diluted EPS
-0.36
-0.9
-0.42
-0.94
Basic Average Shares
1,605,377
1,605,377
1,605,377
1,268,795
Diluted Average Shares
1,605,377
1,605,377
1,605,377
1,268,795
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$578,503
(51.67%↑ Y/Y)
Loss before income
taxes
-$578,503
(51.67%↑ Y/Y)
Loss from operations
-$386,529
(52.19%↑ Y/Y)
Total other expense
-$191,974
(50.58%↑ Y/Y)
Total operating
expenses
$386,529
(-52.19%↓ Y/Y)
Interest expense -
original issuance costs
$119,739
(20.79%↑ Y/Y)
Interest expense - debt
discount
$70,211
(-73.38%↓ Y/Y)
Interest expense
$2,024
(138.12%↑ Y/Y)
General and
administrative
$306,796
(-45.67%↓ Y/Y)
Stock based
compensation
$50,000
(33.33%↑ Y/Y)
Research and development
$29,681
(-85.60%↓ Y/Y)
Marketing expenses
$52
(-54.39%↓ Y/Y)
Buy us a coffee
Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. (SIGY)